a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10567210
Filing Date		2006-02-03
First Named Inventor GOO		SSENS
Art Unit		
Examiner Name		
Attorney Docket Number		NL030978US1

	U.S.PATENTS Remove					
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5293400		1994-03-08	MONOD ET AL	
	2	6499701	B1	2002-12-31	THORNTON ET AL	
	3	6173899	B1	2001-01-16	ROZIN, A.	
	4	5841122		1998-11-24	KIRCHHOFF, G.	
	5 5701121 1997-12-23 MURDOCH, G.		MURDOCH, G.			
	6	5856710		1999-01-05	GENERAL MOTORS CORPORATION	
If you wisl	h to a	dd additional U.S. Pater	t citatio	n information pl	lease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) At Unit At Unit

Application Number			10567210
Filing Date			2006-02-03
	First Named Inventor	G00	SSENS
	Art Unit		
Examiner Name			
Attanesis Dealest Montan			NI 020078LIC4

	_				,			_
	1							
If you wis	h to a	dd additional U.S. Publ	ished Application	n citatio	n information :	olease click the Add	button Add	\neg
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					TENT DOCUM		Remove	\neg
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee Applicant of cited Document	or Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	₌₌
	1	WO9507521	wo	A1	1995-03-16	RENISHAW PLC		
	2	WO9723060	wo	A1	1997-06-26	WHITE ET AL		
	3	GB2129138	GB	A	1984-05-10	SUGAR RESEARCH LIMITED	4	
	4	DE19542214	DE	DE C1		BASNER ET AL		
	5	GB2153410	GB	A	1985-08-21	HARMS ET AL		
If you wis	h to a	dd additional Foreign P	atent Documen	t citation	information p	lease click the Add I	button Add	
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No						T5	
	1	INTERNATIONAL SEARCH REPORT OF INTERNATIONAL APPLICATION NO. PCT/IB2004/051353 CONTAINED IN INTERNATIONAL PUBLICATION NO. WI02005015786.						

2	WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY FOR INTERNATIONAL PUBLICATION NO. PCT/IB2004/051353.	

Date Considered

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Code of USPTO Petert Documents at time USETO.GGU or MREP 991.94. * Enter office that issued the document, by the to-relater code (MPC)
Standard 57.3. * "For uppressee petert of counters, the orbidates or the year of the register time precede the serial review of the pathet document,
* Notice of counters by the appropriate symbols as endicated on the document under WIPO Standard 57.1.6 if possible. * Applicant is to place a check mark here if
Figiglia insignages translation is alsotance.*

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10567210
Filing Date		2006-02-03
First Named Inventor	G00	SSENS
Art Unit		
Examiner Name		
Attorney Docket Number		NL030978US1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign parter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 159(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 137(c)(c)

1	See	attached	certification	statement.	

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/Frank J. Keegan/	Date (YYYY-MM-DD)	2007-09-10
Name/Print	FRANK J KEEGAN	Registration Number	50145

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DIO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.